Protagonist Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Protagonist Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Protagonist Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Protagonist Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Protagonist Therapeutics Inc (Protagonist) is a biopharmaceutical company. It specialises in developing peptide-based new chemical entities, with its leading candidates, Rusfertide and Oral Hepcidin, in advanced clinical stages. Rusfertide (PTG-300) is an injectable hepcidin mimetic for polycythemia vera, enhancing iron regulation and managing hematocrit levels. Icotrokinra, an Oral IL-23R peptide antagonist, targets psoriatic arthritis, ulcerative colitis and Crohn’s disease.PN-881 is an oral IL-17 antagonist that targets psoriasis, psoriatic arthritis, hidradenitis suppurativa and spondyloarthritis. The company is developing peptide antagonists for conditions such as hidradenitis suppurativa, spondyloarthritis, plaque psoriasis and psoriatic arthritis. Protagonist is headquartered in Newark, California, the US.
Headquarters
United States of America
Address
Suite 140, 7707 Gateway Boulevard, Newark, California, 94560
Website
www.protagonist-inc.com
Telephone
1 510 4740170
No of Employees
100
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
PTGX (NASD)
Revenue (2024)
$46.0M
-89.4%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-147.3%
(2024 vs 2023)
Market Cap*
$8.0B
Net Profit Margin (2024)
XYZ
-546.5%
(2024 vs 2023)
* As of and is in US$
Protagonist Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline: |
| Rusfertide (PTG-300): Hematology and Blood Disorders |
| Icotrokinra Oral IL-23R |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2021 | Research Grant | In October, the company announced that it would receive US$7.5 Million as a part of its collaboration agreement with Janssen Biotech, Inc. |
| 2021 | Regulatory Approval | In October, the company announced that removal of FDA clinical hold on the Rusfertide Clinical Development Program. |
| 2021 | Contracts/Agreements | In July, the company entered into an amendment of agreement with Janssen Biotech for the development and commercialization of IL-23 antagonists. |
Competitor Comparison
| Key Parameters | Protagonist Therapeutics Inc | UCB SA | Ardelyx Inc | Rigel Pharmaceuticals Inc | Phathom Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Belgium | United States of America | United States of America | United States of America |
| City | Newark | Anderlecht | Waltham | South San Francisco | Florham Park |
| State/Province | California | Bruxelles-Capitale | Massachusetts | California | New Jersey |
| No. of Employees | 100 | 10,117 | 489 | 172 | 371 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Harold E. Selick, Ph.D. | Chairman | Executive Board | 2009 | 70 |
| Dinesh V. Patel, Ph.D. | Chief Executive Officer; Director; President | Executive Board | 2008 | 68 |
| Asif Ali | Chief Financial Officer; Executive Vice President | Senior Management | 2022 | 51 |
| Arturo Molina, M.D. | Chief Medical Officer | Senior Management | 2022 | 66 |
| Mohammad Masjedizadeh, Ph.D. | Chief Technical Officer; Executive Vice President | Senior Management | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer